Development and Use of Disease-Specific (Reference) Models for Economic Evaluations of Health Technologies: An Overview of Key Issues and Potential Solutions
Cost Effectiveness of Preventive Treatment for Tuberculosis in Special High-Risk Populations
The Economic Costs of Type 2 Diabetes: A Global Systematic Review
Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Choice of Outcome Measure in an Economic Evaluation: A Potential Role for the Capability Approach
Characterizing Heterogeneity Bias in Cohort-Based Models
A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE)
Does it Matter Whether Canada's Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale?
The Silence in Hoch et al.'s Commentary about the Rationale for and Objective(s) of Canada's Separate HTA Process for Cancer Drugs: The Importance of Transparency and Accountability when Allocating Taxpayers' Dollars